<DOC>
	<DOCNO>NCT00837655</DOCNO>
	<brief_summary>The purpose study perform randomize , control clinical trial investigate phosphate binder sevelamer improve insulin resistance glucose handle patient receive maintenance hemodialysis .</brief_summary>
	<brief_title>Effect Sevelamer Glucose Tolerance Insulin Sensitivity Patients With Chronic Renal Failure ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Male female patient 1880 year age chronic renal failure treat maintenance HD &gt; 3 month . Diabetes mellitus Treatment sevelamer within 3 month prior enrollment Acute , clinically significant inflammation within 1 month prior enrollment Pregnancy breastfeed Clinically significant obstipation bowel obstruction Discontinuation previous sevelamer treatment side effect Expected time HD &lt; 1 year Unwillingness undergo investigation followup require protocol Patients receive investigational drug within 1 month prior enrolment Participation another study , may interfere present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>phosphate binder</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>glucose intolerance</keyword>
	<keyword>sevelamer</keyword>
</DOC>